Replies to post #8302 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Wow... part 4 didn't disappoint!

It's great to see Cortex prominently featured in part 4, and to get some inside glimpses into the foundations that COR is built on.

I saw a lot of interesting points in the article for discussion here.

How about this one?

While declaring almost daily that he was about to quit the whole enterprise, Lynch couldn't help himself. The experiments seemed to provide interesting insights into Huntington's, retardation and, out of left field, menopause.

First time I've seen menopause mentioned, and although menopause and ampakines weren't mentioned in the same sentence, I'm still thinking there's a good (and logical) chance we will eventually see them mentioned together.

Not that there aren't bigger fish to fry, but I'm thinking a drug that possibly helps alleviate, or perhaps delays the effects of menopause might have a bit of a market opportunity.

[Aiming4]

Lynch was irate, and for a couple of days everybody avoided him. Then one morning, he was at his desk, smirking like a boy with the key to the cookie jar.

What happened? I asked.

"I can't tell you," he said, his grin growing.

But, of course, it was Lynch; he had to tell. He pointed at his computer monitor on which was displayed information on a company called Memory Pharmaceuticals, founded by Nobel laureate Eric Kandel, and a competitor of Lynch's biotech company, Cortex Pharmaceuticals.

"I'm shorting Eric's stock," Lynch said and cackled.